Science Fiction Becomes Fact: Neoantigen Therapy in Melanoma
Source: Medscape, April 2024
This transcript has been edited for clarity.
Hello. I’m David Kerr, professor of cancer medicine at University of Oxford. I’d like to talk to you today about a study that’s been published recently in The Lancet that is science fiction becoming science fact.
The title of the paper is “Individualised Neoantigen Therapy mRNA-4157 (V940) Plus Pembrolizumab Versus Pembrolizumab Monotherapy in Resected Melanoma (KEYNOTE-942): A Randomised, Phase 2b Study." I’ll talk more about the design in a moment.